PD-1/PD-L1抑制剂在非小细胞肺癌治疗中的研究进展  

Research progress of PD-1/PD-L1 inhibitors in treatment of non-small cell lung cancer

作　　者：张秦畅 汪步海[1] 

机构地区：[1]扬州大学临床医学院江苏省苏北人民医院,江苏扬州225000

出　　处：《中国民康医学》2017年第12期44-46,共3页Medical Journal of Chinese People’s Health

摘　　要：肺癌目前是我国发病率和致死率最高的恶性肿瘤,其中大约85%为非小细胞肺癌(non-small cell lung cancer,NSCLC)。近年来免疫治疗成为了继手术、放疗、化疗等治疗后的新型治疗方向。随着对肿瘤免疫逃逸机制研究的不断深入,通过阻断程序性死亡因子1(programmed cell death 1,PD-1)及其配体1(PD-1 ligand,PD-L1)构成的PD-1/PD-L1通路,证实了PD-1/PD-L1抑制剂在晚期NSCLC患者生存的相关性,以及PD-L1作为疗效预测标志物的价值。本文就PD-1/PD-L1抑制剂用于NSCLC治疗综述如下。Lung cancer is a kind of malignant tumorwith the highest incidence and mortality in China, of which, about 85% are non-small cell lung cancer （ NSCLC）. In recent years, immunotherapy has become a new search direction in the treatment of NSCLC in addition to surgery, radiotherapy, chemotherapy and so on. With the research on the mechanism of tumor immune escape, through blocking the programmed cell death 1 （PD-1）/PD-1 ligand （PD-L1） pathway, the relevance of PD-1/PD-L1 inhibitors for survival in the patients with advanced NSCLC was confirmed, and the value of PD-L1 as a predictive marker for efficacy was demonstrated. This article reviewed the achievements of PD-1/PD-L1 inhibitors in the NSCLC therapy.

关 键 词：非小细胞肺癌 PD-1/PD-L1 抗PD-1单抗 免疫治疗 

分 类 号：R734.2[医药卫生—肿瘤]